Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yishen Daluo Yin Granule for Relapsing-remitting Multiple Sclerosis
NCT07029867Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Traditional Chinese Medicine decoction, Herbal combination
01
Overview
Randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing YSDLY group with Placebo group (2 arms). Primary endpoint: Proportion of patients without combined unique active lesions at 24 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Yishen Daluo Yin
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT07029867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029867.